case_images: PMC9639856_01
case_images: Cytokine monitoring after CART infusion. CART, chimeric antigen receptor T-cell; IL, interleukin; TNF, tumor necrosis factor; CRP, C-reactive protein.
case_images: fonc-12-932254-g001.jpg
case_images: PMC9639856_01_fonc-12-932254-g001.jpg
case_images: f1
case_images: Cytokine monitoring after infusion of CART is shown in  Figure 1 .
case_images: Timeline of treatment and efficacy. *multiply: six courses of alternative therapy with Hyper-CVAD-A (cyclophosphamide, vindesine, doxorubicin, and dexamethasone), MAVP (methotrexate, cytarabine, vindesine, and dexamethasone).
case_images: fonc-12-932254-g002.jpg
case_images: PMC9639856_01_fonc-12-932254-g002.jpg
case_images: f2
case_images: The treatment regimen of the patient is depicted in  Figure 2 .
case_images: CART cell expansion in vivo. CART, chimeric antigen receptor T-cell.
case_images: fonc-12-932254-g003.jpg
case_images: PMC9639856_01_fonc-12-932254-g003.jpg
case_images: f3
case_images: CART cells were monitored by reverse transcription polymerase chain reaction ( Figure 3 ). CART cells reached their first peak 6 d after infusion and then dropped.